Eli Lilly CFO Sees GLP-1 Drugs As Key Growth Driver
GLP-1 drugs drive growth
Story updates
02:26:56 PM UTC
SquawkNews
ELI LILLY CFO: INJECTABLE GLP-1 DRUGS REMAIN KEY GROWTH DRIVER, ACCOUNT FOR 3 OUT OF 4 NEW PATIENT STARTS
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.